Circulating Biomarkers of Mitochondrial Dysfunction and Oxidative Stress in Premature Coronary Artery Disease: Association with Endothelial Dysfunction and Clinical Disease Severity—A Systematic Review and Meta-analysis
Background: Premature coronary artery disease (PCAD) is an important cause of cardiovascular morbidity and mortality among younger adults and is associated with accelerated atherosclerosis, endothelial dysfunction, and increased oxidative stress. Mitochondrial abnormalities contribute to vascular injury through impaired mitochondrial respiration, excessive reactive oxygen species production, oxidative DNA damage, and reduced nitric oxide bioavailability. Circulating biomarkers, including mitochondrial DNA copy number (mtDNA-CN), mitochondrial DNA deletions, malondialdehyde (MDA), lipid peroxides, reduced glutathione (GSH), and oxidative DNA damage markers, have emerged as potential indicators of vascular dysfunction and coronary disease severity. However, their diagnostic and prognostic significance in PCAD remains uncertain. Objective: To systematically evaluate the association of circulating biomarkers of mitochondrial dysfunction and oxidative stress with PCAD, endothelial dysfunction, and clinical disease severity, with particular emphasis on biomarker concentrations, diagnostic performance, endothelial flow-mediated dilation, and angiographic disease burden. Methods: A systematic review was undertaken using clinical evidence identified through PubMed/MEDLINE, publisher-hosted databases, and supplementary reference searches covering studies available through November 2026. Eligible investigations included case–control studies, prospective observational cohorts, and published systematic reviews evaluating circulating mitochondrial and oxidative-stress biomarkers among patients with premature or early-onset coronary disease. Data were extracted on participant characteristics, age at disease onset, mitochondrial DNA alterations, oxidative-stress markers, antioxidant status, flow-mediated dilation (FMD), coronary angiographic findings, and clinical outcomes. Associations were evaluated using reported odds ratios (ORs), hazard ratios (HRs), correlation coefficients, receiver operating characteristic (ROC) analyses, and corresponding confidence intervals. Published quantitative estimates were synthesized according to biomarker category, study population, and clinical outcome. Results: A total of 1,462 records were identified, comprising 1,428 database records and 34 records from additional sources. Following removal of 286 duplicates, 1,176 records underwent title and abstract screening, of which 1,079 were excluded. Ninety-seven full-text articles were assessed for eligibility, and 73 were excluded because of unavailable premature CAD subgroup data (19), absence of mitochondrial or oxidative-stress biomarker assessment (18), unavailable endothelial dysfunction or disease-severity outcomes (14), insufficient quantitative data (12), or overlapping study populations (10). Twenty-four studies were included in the qualitative synthesis, with 16 designated for quantitative synthesis. An early-onset CAD case–control investigation involving 268 participants demonstrated reduced leukocyte mtDNA-CN and increased mitochondrial DNA 4977-bp deletion among affected patients. ROC analysis demonstrated an area under the curve (AUC) of 0.902 (95% confidence interval [CI] 0.867–0.937) for mtDNA-CN and 0.762 (95% CI 0.691–0.834) for mitochondrial DNA deletion. A separate PCAD investigation involving 60 participants identified reduced glutathione as an inverse correlate of disease (adjusted OR 0.569; 95% CI 0.375–0.864), with an AUC of 0.88. Among 115 premature ST-segment elevation myocardial infarction patients and 55 controls, lipid peroxide levels were elevated (15.8 versus 4.1 in the reported assay units), whereas reduced glutathione levels were decreased (3.8 versus 5.2). In a larger case–control study involving 3,064 participants, each standard-deviation decrease in mtDNA-CN was associated with a 1.14-fold increase in coronary artery disease odds. Among 105 patients with stable coronary disease, an elevated lactate-to-pyruvate ratio was associated with a 1.09-percentage-point reduction in FMD (P = 0.03). A published meta-analysis encompassing 29 cohorts and 646,398 participants reported a coronary heart disease HR of 1.18 (95% CI 0.92–1.50; I² = 91%) for lower mitochondrial DNA copy number, without demonstrating a statistically significant association. Evidence directly relating circulating mitochondrial biomarkers to Gensini and SYNTAX scores in strictly defined PCAD populations remained limited. Conclusion: Circulating mitochondrial DNA abnormalities and oxidative-stress biomarkers demonstrate potentially important associations with premature coronary artery disease. Reduced mitochondrial DNA copy number, increased mitochondrial genomic damage, enhanced lipid peroxidation, and impaired antioxidant defenses may reflect accelerated vascular injury and altered endothelial function. However, substantial methodological heterogeneity, differences in age-based definitions of PCAD, and limited prospective validation restrict their current clinical applicability. Integration of mitochondrial genomic markers, oxidative-stress indices, direct endothelial function measurements, and coronary angiographic severity scores may improve future cardiovascular risk stratification. Larger prospective studies with standardized biomarker assays and longitudinal clinical outcomes are required to establish independent predictive utility.